Considerations for using potential surrogate endpoints in cancer screening trials.

Webb AB, Berg CD, Castle PE, Crosby D, Etzioni R, Kessler LG, Menon U, Parmar M, Steele RJC, Sasieni PD

DOI: 10.1016/s1470-2045(24)00015-9
Published: 2024 May
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-24-00015-9,
  title = {Considerations for using potential surrogate endpoints in cancer screening trials.},
  author = {Webb AB and Berg CD and Castle PE and Crosby D and Etzioni R and Kessler LG and Menon U and Parmar M and Steele RJC and Sasieni PD},
  year = {2024},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(24)00015-9},
  url = {https://doi.org/10.1016/s1470-2045(24)00015-9}
}

RIS

TY  - JOUR
TI  - Considerations for using potential surrogate endpoints in cancer screening trials.
AU  - Webb AB
AU  - Berg CD
AU  - Castle PE
AU  - Crosby D
AU  - Etzioni R
AU  - Kessler LG
AU  - Menon U
AU  - Parmar M
AU  - Steele RJC
AU  - Sasieni PD
PY  - 2024
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(24)00015-9
UR  - https://doi.org/10.1016/s1470-2045(24)00015-9
ER  -

APA

AB, W., CD, B., PE, C., D, C., R, E., LG, K., U, M., M, P., RJC, S., & PD, S. (2024). Considerations for using potential surrogate endpoints in cancer screening trials.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(24)00015-9

Source records

pubmed · retrieved 2026-09-26T23:16:16.880Z